PE20030448A1 - Formas pseudopolimorficas de caverdilol - Google Patents
Formas pseudopolimorficas de caverdilolInfo
- Publication number
- PE20030448A1 PE20030448A1 PE2002000938A PE2002000938A PE20030448A1 PE 20030448 A1 PE20030448 A1 PE 20030448A1 PE 2002000938 A PE2002000938 A PE 2002000938A PE 2002000938 A PE2002000938 A PE 2002000938A PE 20030448 A1 PE20030448 A1 PE 20030448A1
- Authority
- PE
- Peru
- Prior art keywords
- refers
- forms
- pseudopolymorphic form
- pseudopolimorphic
- caverdilol
- Prior art date
Links
- -1 4-CARBAZOLYLOXY Chemical class 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000002329 infrared spectrum Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A LA FORMA PSEUDOPOLIMORFICA DE (+/-) 1-(4-CARBAZOLILOXI)-3-[2-(2-METOXIFENOXI)ETILAMINO]-2-PROPANOL O FORMAS OPTICAMENTE ACTIVAS O SALES FARMACEUTICAMENTE ACEPTABLES. LA FORMA PSEUDOPOLIMORFICA ES UN HIDRATO Y PRESENTA UN PATRON DE DIFRACCION DE RAYOS X CARACTERISTICO OBTENIDO CON UNA RADIACION DE Cu kO1- A 2 0 IGUAL 7,0; 8,3; 11,5; 15,7; 17,2, UN ESPECTRO INFRARROJO CON PICOS AGUDOS A 3526 cm-1, 3492 cm-1 Y 3400 cm-1 Y UN PUNTO DE FUSION APROXIMADO DE T = 94°C A 96°C. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DE 5% A 60% DEL COMPUESTO MENCIONADO; UNO O MAS ADYUVANTES QUE NO SON ACTIVOS EN SUPERFICIE SELECCIONADO DE POLIETILENGLICOL CON UN PESO MOLECULAR DE 200 A 20 000; UNO O MAS TENSIOACTIVOS NO INONICOS COMO POLIOXIETILEN-POLIOXIPROPILENO Y DIOXIDO DE SILICO ALTAMENTE DISPERSADO. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE HIPERTENSION, INSUFICIENCIA CARDIACA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01123422 | 2001-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030448A1 true PE20030448A1 (es) | 2003-06-19 |
Family
ID=8178782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000938A PE20030448A1 (es) | 2001-09-28 | 2002-09-24 | Formas pseudopolimorficas de caverdilol |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20030119893A1 (es) |
| EP (1) | EP1432681B1 (es) |
| JP (1) | JP2005507899A (es) |
| KR (1) | KR100752549B1 (es) |
| CN (1) | CN1308307C (es) |
| AR (1) | AR036689A1 (es) |
| AT (1) | ATE369339T1 (es) |
| AU (1) | AU2002338726B2 (es) |
| BR (1) | BR0212927A (es) |
| CA (1) | CA2460486A1 (es) |
| DE (1) | DE60221683T2 (es) |
| ES (1) | ES2291503T3 (es) |
| GT (1) | GT200200198A (es) |
| MX (1) | MXPA04002826A (es) |
| PA (1) | PA8555201A1 (es) |
| PE (1) | PE20030448A1 (es) |
| PL (1) | PL370412A1 (es) |
| RU (1) | RU2308449C2 (es) |
| UY (1) | UY27461A1 (es) |
| WO (1) | WO2003029214A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004501191A (ja) * | 2000-06-28 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | カルベジロール |
| MXPA04006909A (es) | 2002-01-15 | 2005-04-19 | Teva Pharma | Solidos cristalinos de carvedilol y procesos para su preparacion. |
| MXPA04012923A (es) | 2002-06-27 | 2005-03-31 | Sb Pharmco Inc | Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento. |
| SI21616A (sl) * | 2003-09-02 | 2005-04-30 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Nove kristalne oblike karvedilola |
| US20070043099A1 (en) * | 2005-06-09 | 2007-02-22 | Igor Lifshitz | Crystalline forms of carvedilol and processes for their preparation |
| WO2008002683A2 (en) * | 2006-06-28 | 2008-01-03 | Teva Pharmaceutical Industries Ltd. | Polymorphous forms of carvedilol phosphate |
| US20080292695A1 (en) * | 2006-12-01 | 2008-11-27 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
| US20090028935A1 (en) * | 2006-12-01 | 2009-01-29 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
| US20080207726A1 (en) * | 2007-02-26 | 2008-08-28 | Santiago Ini | Process for the purification of carvedilol or its salts thereof |
| US20080249317A1 (en) * | 2007-04-04 | 2008-10-09 | Apotex Inc. | Novel amorphous form of carvedilol phosphate and processes for the preparation thereof |
| TWI415604B (zh) * | 2009-09-29 | 2013-11-21 | Tsh Biopharm Corp Ltd | 調控釋放卡菲蒂羅劑型 |
| US20110229564A1 (en) * | 2010-03-22 | 2011-09-22 | Amneal Pharmaceuticals, L.L.C. | Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2815926A1 (de) * | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE3319027A1 (de) * | 1983-05-26 | 1984-11-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten |
| GB9113802D0 (en) * | 1991-06-26 | 1991-08-14 | Smithkline Beecham Plc | Medicaments |
| US5393772A (en) * | 1993-11-24 | 1995-02-28 | Boehringer Mannheim Pharmaceuticals Corporation | Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation |
| EP0893440A1 (en) * | 1997-07-22 | 1999-01-27 | Roche Diagnostics GmbH | Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it |
| HU227441B1 (en) * | 1997-11-24 | 2011-06-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Process for producing carvedilol, enantiomers and salts thereof |
| US20010036959A1 (en) * | 2000-04-03 | 2001-11-01 | Gabel Rolf Dieter | Carvedilol-hydrophilic solutions |
| JP2004501191A (ja) * | 2000-06-28 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | カルベジロール |
-
2002
- 2002-09-18 KR KR1020047004578A patent/KR100752549B1/ko not_active Expired - Fee Related
- 2002-09-18 EP EP02777139A patent/EP1432681B1/en not_active Expired - Lifetime
- 2002-09-18 AT AT02777139T patent/ATE369339T1/de not_active IP Right Cessation
- 2002-09-18 BR BR0212927-2A patent/BR0212927A/pt not_active IP Right Cessation
- 2002-09-18 CN CNB028187415A patent/CN1308307C/zh not_active Expired - Fee Related
- 2002-09-18 JP JP2003532464A patent/JP2005507899A/ja active Pending
- 2002-09-18 CA CA002460486A patent/CA2460486A1/en not_active Abandoned
- 2002-09-18 AU AU2002338726A patent/AU2002338726B2/en not_active Ceased
- 2002-09-18 MX MXPA04002826A patent/MXPA04002826A/es active IP Right Grant
- 2002-09-18 PL PL02370412A patent/PL370412A1/xx not_active Application Discontinuation
- 2002-09-18 DE DE60221683T patent/DE60221683T2/de not_active Expired - Fee Related
- 2002-09-18 ES ES02777139T patent/ES2291503T3/es not_active Expired - Lifetime
- 2002-09-18 WO PCT/EP2002/010451 patent/WO2003029214A1/en not_active Ceased
- 2002-09-18 RU RU2004113209/04A patent/RU2308449C2/ru not_active IP Right Cessation
- 2002-09-24 PE PE2002000938A patent/PE20030448A1/es not_active Application Discontinuation
- 2002-09-25 PA PA20028555201A patent/PA8555201A1/es unknown
- 2002-09-26 US US10/255,290 patent/US20030119893A1/en not_active Abandoned
- 2002-09-27 AR ARP020103656A patent/AR036689A1/es not_active Application Discontinuation
- 2002-09-27 UY UY27461A patent/UY27461A1/es not_active Application Discontinuation
- 2002-09-27 GT GT200200198A patent/GT200200198A/es unknown
-
2004
- 2004-04-20 US US10/827,859 patent/US20040198812A1/en not_active Abandoned
-
2006
- 2006-01-05 US US11/325,754 patent/US20060148878A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002338726B9 (en) | 2003-04-14 |
| DE60221683T2 (de) | 2008-04-30 |
| CN1308307C (zh) | 2007-04-04 |
| CA2460486A1 (en) | 2003-04-10 |
| US20040198812A1 (en) | 2004-10-07 |
| ATE369339T1 (de) | 2007-08-15 |
| UY27461A1 (es) | 2003-06-30 |
| AU2002338726B2 (en) | 2007-03-15 |
| ES2291503T3 (es) | 2008-03-01 |
| GT200200198A (es) | 2003-06-19 |
| PA8555201A1 (es) | 2003-12-10 |
| CN1558900A (zh) | 2004-12-29 |
| PL370412A1 (en) | 2005-05-30 |
| EP1432681A1 (en) | 2004-06-30 |
| AR036689A1 (es) | 2004-09-29 |
| DE60221683D1 (en) | 2007-09-20 |
| US20030119893A1 (en) | 2003-06-26 |
| JP2005507899A (ja) | 2005-03-24 |
| KR100752549B1 (ko) | 2007-08-30 |
| WO2003029214A1 (en) | 2003-04-10 |
| BR0212927A (pt) | 2004-10-13 |
| KR20040047872A (ko) | 2004-06-05 |
| EP1432681B1 (en) | 2007-08-08 |
| MXPA04002826A (es) | 2004-07-02 |
| US20060148878A1 (en) | 2006-07-06 |
| RU2308449C2 (ru) | 2007-10-20 |
| RU2004113209A (ru) | 2005-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030448A1 (es) | Formas pseudopolimorficas de caverdilol | |
| AR015133A1 (es) | Una forma cristalina de (+/-)1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, sales farmacologicamente aceptables o formas opticas de lasmismas, un procedimiento para preparar y aislar dicha forma cristalina en forma sustancialmente pura, una composicion farmaceutica que comprende dic | |
| AR094217A2 (es) | Monoetanosulfonato de 3-z-[1-(4-(n-((4-metil-piperazina-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoxicarbonil-2-indolinona y su utilizacion como medicamento | |
| USD914048S1 (en) | Portable communications device with a graphical user interface | |
| CY1123820T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν μελοξικαμη και ριζατριπτανη | |
| USD826854S1 (en) | Portable power bank | |
| USD842475S1 (en) | Dental implant | |
| USD872271S1 (en) | Medical x-ray photographing apparatus | |
| KR102510156B1 (ko) | 자동 이동식 살균장치 | |
| CO2021006482A2 (es) | Ureas cíclicas | |
| PE20090185A1 (es) | Formulaciones farmaceuticas que contienen un inhibidor sglt2 | |
| CY1113330T1 (el) | Υποκατεστημενες με φθοριο κυκλοαλκανοϊνδολες και η χρηση τους ως ανταγωνιστες των υποδοχεων προσταγλανδινης d2 | |
| JP2017040940A5 (ja) | 近視予防物品及び近視予防セット | |
| NO20013469D0 (no) | Fremgangsmåter for glukagonsuppresjon | |
| PE20021159A1 (es) | Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo | |
| AR086971A2 (es) | Composiciones orales y sistemas de liberacion | |
| CO2019002555A2 (es) | Composición farmacéutica | |
| BR0204370A (pt) | Dispositivo de recepção e captação | |
| ATE475667T1 (de) | Templat-fixierte peptidomimetika | |
| MX2023006020A (es) | Combinacion que comprende abemaciclib y acido 6-(2,4-diclorofenil)-5-[4-[(3s)- 1-(3-fluoropropil)pirrolidin-3-il ]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico. | |
| CO2020011989A1 (es) | Composición de protección solar pulverizable | |
| ES2422730T3 (es) | Sales de tiotropio, procedimiento para su preparación, así como formulaciones de medicamentos que las contienen | |
| CY1124733T1 (el) | Antimykhtiaσιko φαρμακευτικο σκευασμα | |
| USD773668S1 (en) | X-ray tube for medical use | |
| PH12018502668A1 (en) | Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |